Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma.

ESMO Open · 2025 · PMC12173038 · PMID 40479863

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

nearly reached significanceP = 0.06so close (0.05 < p ≤ 0.1)

ECOG PS 2/3 was associated with shorter OS (HR 2.45, 95% CI 1.23-4.86, P = 0.011) and the presence of liver metastases nearly reached significance for shorter OS (HR 1.71, 95% CI 0.98-2.99, P = 0.06) adjusted for number of prior lines and bone metastases.

also in 20 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.